Why AbbVie Could Join the M&A Mania Soon Post author:Sam Post published:January 30, 2018 Post category:BioPharma The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash. Source: BioSpace You Might Also Like 3 Biotech Stocks Able to Weather an Unstable Administration February 9, 2017 Pfizer Turns to to Explore $2 Billion Sale of Certain Assets February 1, 2017 Once-Prominent Bay Area Biotech VC, Faces Up to 30 Years in Prison September 20, 2017